

**Anti-Hyperglycemic and Anti-Hyperlipidemic Potentials of Methanol Leaf  
Extracts of *Aframomum melegueta* and *Piper guineense***

**Aim:** The study investigated the anti-hyperglycemic and anti-hyperlipidemic potentials of methanol extracts of *Piper guineense* and *Aframomum melegueta* leaves with a view to utilizing the plants in the treatment and management of cardiovascular disorders.

**Methodology:** Twenty-eight healthy albino rats were randomly divided into seven equal groups: Group I received normal saline (2 ml/kg bwt); Group II received a single dose of alloxan (150 mg/kg bwt) intraperitoneally; Group III received alloxan (150 mg/kg bwt) + glibenclamide (5 mg/kg bwt); Group IV received alloxan (150 mg/kg bwt) + PG (200 mg/kg bwt); Group V received alloxan (150 mg/kg bwt) + PG (400 mg/kg bwt); Group VI received alloxan (150 mg/kg bwt) + AM 200 (mg/kg bwt); Group VII received alloxan (150 mg/kg bwt) + AM (400 mg/kg bwt). The blood glucose level was determined before and after treatment with the extracts. The lipid: (total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL) were estimated using the Randox diagnostic kits.

**Results:** The results revealed that alloxan was able to induce hyperglycemia at 150 mg/kg bwt and post-treatment with *P. guineense* and *A. melegueta* at 200 mg/kg and 400 mg/kg bwt were able to significantly lower the blood glucose level which was quite apparent in AM treated groups. Also, the extracts at 200 mg/kg and 400 mg/kg were able to bring a significant ( $p < 0.05$ ) reduction in TC, TG and LDL concentrations when compared to the alloxan treated group with the highest reduction in AM treated groups.

**Conclusion:** These results revealed that the methanol extract of *P. guineense* and *A. melegueta* elicited anti-hyperglycemic and anti-hyperlipidemic potentials of the extracts with the highest effect observed in *A. melegueta* treated rats.

**Keywords:** -Anti-hyperglycemic, Anti-hyperlipidemic, *Piper guineense* and *Aframomum melegueta*

## 31 1. INTRODUCTION

32 *Diabetes mellitus* (DM) is a chronic metabolic disorder and is becoming a global health concern because  
33 of the increase in its prevalence. However, hyperglycemia and hyperlipidemia are some of the factors  
34 indicating this metabolic syndrome[1]. Hyperglycemia is a condition in which an excessive amount of  
35 glucose circulates in the blood plasma. Diabetic neuropathy may be a result of long-term hyperglycemia.  
36 Hyperlipidemia is characterized by abnormal elevation in plasma triglyceride, cholesterol and low density  
37 lipoprotein-cholesterol (LDL-c) and very low lipoprotein - cholesterol (VLDL-c) and has also been  
38 reported to be the most prevalent indicator for susceptibility to atherosclerotic heart disease [2]. Also,  
39 high blood glucose levels are associated with low level of high-densitylipoprotein cholesterol (HDL-c)  
40 and increase of LDL-c cholesterol, thus increasing risk of coronary heart diseases. Therefore, it is vital to  
41 manage both diabetes and lipid levels [3]

42 The increase in demand for cheaper therapeutics with no/minimum side effects is stimulating interest in  
43 studying the use of natural products for the treatment and management of diseases [4]. The medicinal  
44 values of these plants are usually due to the presence of phytochemicals [5].

45 *P. guineense* belongs to the family Piperaceae commonly known as West African Black Pepper. It is a  
46 climbing plant climbing up to 12m high by its adventitious rootlets. It is known with different vernacular  
47 names in Nigeria which include 'Uziza' in Igbo, and 'Iyere' in Yoruba. The seeds are smooth and are  
48 prolate-elliptically shaped. The seeds, leaves and sometimes the stems are used in preparing soup. It  
49 imparts "heat" and a spicy pungent aroma to food. The plant is utilized for a variety of purposes which  
50 include human dietaries, preservative, bio-control agent as well as traditional medicine [6].

51 Previous phytochemical studies of *P. guineense* seed extract revealed the presence of various substances  
52 such as alkaloids, flavonoids, tannins triterpenoids, cardiac glycosides and saponins[7]. Pharmacological  
53 and physiological studies of *P. guineense* extract showed depolarizing neuromuscular blocking action,  
54 insecticidal properties, sexual behavioural effect and antifungal activity [8] and edema in gastrointestinal  
55 tract, urinary bladder and adrenal glands and immunotoxicological effects [9].

56 *Aframomum melegueta* K. Schum belongs to the ginger family (Zingiberaceae) and it is commonly known  
57 as grains of paradise or alligator pepper [10]. It is variously known locally as *oseoji* in Igbo,  
58 *ataare* in Yoruba, and *cittáá* in Hausa of Nigeria. The seeds of *A. melegueta* have been variously reported to  
59 be rich in carbohydrates, crude fibre, and bulk minerals [11] suggesting it to be of good nutritional  
60 quality, and hence justifying its incorporation into diet. The report of [12, 13], NMR and GC-MS analyses  
61 of the chloroform extract of the seeds and essential oils from various plant parts, respectively show the  
62 plant to be rich in secondary metabolites such as modified gingerols, paradols and shogaols. These

63 metabolites account for some of peppery taste of the seeds [14]. The use of *A. melegueta* in traditional  
64 medicine in treating diabetes has been age long. The essential oils, polyphenol profile and antioxidant  
65 activity of *Aframomum melegueta*, have been reported [15,17,18,19]. It is used medicinally to treat many  
66 diseases including measles, leprosy; to stop lactation and post-partum haemorrhage, as anti-diarrhea  
67 and anti-inflammatory activity which may be due to prostaglandin inhibition, and membrane stabilizing  
68 activity respectively [20].

69 Many studies have been carried out on the seeds of these plants but there is dearth of scientific  
70 information on the leaves of these plants. Hence, this study investigated the anti-hyperglycemia and the  
71 anti-hyperlipidemic effects of the leaf extracts of *A. melegueta* and *P. guineense*.

72

## 73 2. MATERIALS AND METHODS

### 74 2.1 Chemicals

75 All chemicals and drugs used were obtained commercially and of analytical grade.

#### 76 2.1.1 Collection of plant materials

77 The leaves of *A. melegueta* and *P. guineense* were collected in February, 2015 at Okuku, Odo-Otin local  
78 government, Osun State, Nigeria. It was identified and authenticated at IFE  
79 herbarium (17525), Obafemi Awolowo University, Ile-Ife.

80 The methanolic extracts of *A. melegueta* and *P. guineense* were separately prepared. The leaves were dried  
81 under shade and ground into powder. Typically, the powder (200g) was macerated in 2.5 L methanol  
82 (70%) at room temperature for 72h. It was then filtered using muslin cloth. The filtrates were allowed to  
83 settle, decanted and filtered using filtration assembly. The filtrates were evaporated using rotary evaporator  
84 and then freeze dried using lyophilizer. The extracts were stored in air tight container in a refrigerator until  
85 used.

### 86 2.2 Experimental Animals

87 Adult female and male albino rats (28) weighing between 120-150 g were obtained from the Animal  
88 House, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife. The rats were housed in polyethylene  
89 cages at the Animal House, Department of Biochemistry, Adeleke University, Ede and were kept under  
90 standard conditions; food and water were supplied *ad libitum*. They were allowed to acclimatized for a  
91 period of 14 days.

### 92 2.3 Grouping and Treatment of Animals

93 The rats were randomly assigned into seven groups of four rats in each group as follows:

94 Group I: Control (Normal saline)

95 Group II: Alloxan Treated (150 mg/kg bwt)

96 Group III: Alloxan + Glibenclamide (5mg/kg bwt)

97 Group IV: Alloxan + PG (200 mg/kg bwt)

98 Group V: Alloxan + PG (400 mg/kg bwt)

99 Group VI: Alloxan + AM (200 mg/kg bwt)

100 Group VII: Alloxan + AM (400 mg/kg bwt)

101 The extracts and the reference drug (Glibenclamide) were administered orally. The doses of the extract  
102 was determined according to the acute toxicity study carried out by []

#### 103 **2.4 Induction of Diabetes and Treatment with the Extracts**

104 The animals were allowed to fast overnight and diabetes was induced by a single intra-peritoneal injection  
105 of alloxan monohydrate (150 mg/kg bwt). Increase glucose level was monitored 3 days after injection by  
106 measuring the tail vein blood glucose level using glucometer. The induced rats were orally treated with  
107 the extracts for 7 days.

#### 108 **2.5 Determination of Blood Glucose Levels**

109 The level of blood glucose was determined according to the method described by [21] before and after  
110 treatment with the extract and standard drug by using a glucometer. The rats were subjected to fasting for  
111 12-18 h with free access to water prior to the administration of the extract and the blood glucose level was  
112 measured. After the last treatment with the extracts, the animals were fasted overnight and the blood  
113 samples were collected for the determination of the blood glucose concentration.

#### 114 **2.6 Sacrificing and Preparation of Blood Plasma**

115 The rats were sacrificed under mild anesthesia with ether, 24 h after the last treatment (oral administration  
116 of extracts and drug). Blood was collected by cardiac puncture into bottles containing anticoagulant  
117 (trisodium citrate, 3.8% w/v) and mixed gently. Blood plasma was prepared using standard procedure as  
118 reported and modified by Bode and Oyedapo [22]. Blood sample was centrifuged on Bench Centrifuge  
119 Model 90-2 (Searchtech Instrument England, UK.) at 3000 rpm for 10 min. The supernatant (plasma) was  
120 collected into sterile bottles, labeled and stored in freezer for biochemical analyses.

#### 121 **2.7 Estimation of Plasma Lipid Profiles**

122 Plasma lipid profiles: triacylglycerol (TG), total cholesterol (TC), High density lipoprotein cholesterol  
123 (HDL-c), low density lipoprotein cholesterol (LDL-c), were estimated spectrophotometrically using  
124 Randox assay kits.

## 125 2.8 Statistical analysis

126 The data were statistically analyzed using t-test and ANOVA with the aid of SARSsoftware package. The  
127 level of statistical significance was also compared using Duncan's multiple range test  $p < 0.05$ .

## 128 3. RESULTS

### 129 Yield of the Extract

130 3.1 The methanol leaf extract obtained from 500g of powdered leaf weighed 5.6g which was 1.12% of the  
131 starting material.

132 4.1.2 The methanol leaf extract obtained from 500g of powdered leaf weighed 97.69g which was  
133 19.5% of the starting material.

### 134 3.1 Blood Glucose Level

135 In Table 1 is the summary of the initial and final concentrations of blood glucose. After induction of  
136 hyperglycemia with alloxan monohydrate, there was a significant increase ( $P < 0.05$ ) in blood glucose level  
137 of other experimental groups when compared with the normal control group. After treatment the extracts  
138 at 200 mg/kg and 400 mg/kg, the blood glucose level was significantly reduced ( $P < 0.05$ ) when compared  
139 to the alloxan treated rats. This indicated the anti-hyperglycemic potentials of the extracts.

140 **Table 1: Effects of Methanol Leaf Extract of *P. guineense* and *A. melegueta* on Blood Glucose**  
141 **Concentration (mg/dl) of Alloxan-induced Hyperglycemic Rats**

Treatment Group	Initial Blood Glucose (mg/dl)	Final Blood Glucose (mg/dl)	% Change
Control	80.50 ± 2.02	75.75 ± 1.11	5.90
Alloxan Treated	79.25 ± 0.85 <sup>b</sup>	199.00 ± 1.68 <sup>a</sup>	151.10
Alloxan + Gilbenclamide (5mg/kg bwt)	59.25 ± 0.48 <sup>a</sup>	95.75 ± 0.85 <sup>b</sup>	61.60
Alloxan + <i>P. guineense</i> (200 mg/kg bwt)	68.25 ± 0.35 <sup>a</sup>	137.75 ± 2.66 <sup>b</sup>	101.83
Alloxan + <i>P. guineense</i> (400 mg/kg bwt)	75.50 ± 1.09 <sup>b</sup>	114.50 ± 3.07 <sup>b</sup>	51.66
Alloxan + <i>A. melegueta</i> (200 mg/kg bwt)	79.50 ± 0.87 <sup>b</sup>	65.50 ± 1.96 <sup>b</sup>	-17.61

---

Alloxan + <i>A. melegueta</i> (400 mg/kg bwt)	74.25 ± 0.91 <sup>b</sup>	72.25 ± 1.58 <sup>b</sup>	2 .69
---	---------------------------	---------------------------	-------

---

142

143 Each value represented mean ± SEM, n = 4 readings. Values with different superscript  
144 alphabet are significantly different at P<0.05.

145 **3.2 Lipid Profiles**

146 In Table 2 is the summary of the effect of the extracts on the plasma lipid profile of alloxan-induced  
147 hyperglycemia rats. There was significant increase in the concentrations of TC, TG and LDL-c but a  
148 decrease in HDL-c of the alloxan treated group when compared to the control group. However, treatment  
149 with the extracts at 200 and 400 mg/kg bwt caused a significant reduction in the concentrations of TC, TG  
150 and LDL-c but an increase in HDL-c.

151

152

153

UNDER PEER REVIEW

154 **Table 2: The Effectsof Methanol Leaf Extract of*P. guineense* and *A. meleguetaon* LipidProfile**  
 155 **(mmol/L)of Alloxan-induced HyperglycemicRats**

Treatment Group	TC(mmol/L)	TG(mmol/L)	HDL(mmol/L)	LDL(mmol/L)
Control	5.99 ± 0.003	1.61 ± 0.001	4.54 ± 0.001	0.714 ± 0.008
Alloxan Treated	15.82 ± 0.019 <sup>a</sup>	4.89 ± 0.002 <sup>a</sup>	0.02 ± 0.001 <sup>a</sup>	13.58 ± 0.019 <sup>a</sup>
Alloxan + Gilbenclamide (5mg/kg bwt)	8.253 ± 0.019 <sup>b</sup>	1.96 ± 0.310 <sup>b</sup>	3.27 ± 0.019 <sup>b</sup>	4.09 ± 0.014 <sup>c</sup>
Alloxan + PG (200 mg/kg bwt)	9.448±0.102 <sup>b</sup>	3.862±0.021 <sup>b</sup>	2.266±0.387 <sup>b</sup>	5.426±0.061 <sup>b</sup>
Alloxan + PG (400 mg/kg bwt)	7.318±0.018 <sup>b</sup>	2.008±0.003 <sup>b</sup>	4.364±0.017 <sup>b</sup>	5.426±0.061 <sup>b</sup>
Alloxan + AM (200 mg/kg bwt)	9.35 ± 0.046 <sup>b</sup>	0.961 ± 0.032 <sup>b</sup>	6.95 ± 0.04 <sup>b</sup>	1.05 ± 0.10 <sup>b</sup>
Alloxan + AM (400 mg/kg bwt)	8.411 ± 0.062 <sup>b</sup>	2.381 ± 0.02 <sup>b</sup>	7.12 ± 0.002 <sup>b</sup>	0.214 ± 0.07 <sup>b</sup>

156  
 157 Values are mean ± SEM of **four** determinations. Values with different superscript alphabet are  
 158 significantly different at P<0.05.

159 **4. Discussion**

160 The study evaluated anti-hyperglycemia and anti-hyperlipidemic effects of *A. melegueta* and *P. guineense*  
 161 leaf extracts at 200 mg/kg bwt and 400 mg/kg bwt. The dose was chosen based on the reports of previous  
 162 studies [23, 24, 25]. After the administration of alloxan monohydrate, there was significant increase (p <  
 163 0.05) in the blood glucose level of the alloxan-treated group when compared to the normal control  
 164 group (Table 1). Elevated value of fasting blood glucose concentration observed in alloxan treated rats may  
 165 be due to the toxic effect of alloxan on islet beta cells of the pancreas through its ability to induce reactive  
 166 oxygen species (ROS) formation, resulting in the necrosis of the pancreas and loss of capacity of the  
 167 pancreas to secrete insulin resulting to hyperglycemia [26,27,28].

168 Chronic exposure to hyperglycemia is the primary casual factor in the pathogenesis of diabetic  
 169 complications and cause changes in vascular tissue which promote atherosclerosis [29). Our findings is in  
 170 agreement with the report of earlier studies that administration of alloxan at the dose of 250mg/kg was  
 171 able to increase to elevate the fasting blood sugar levels [21, 29]. However, post-treatments with



172 *P. guineense* and *A. melegueta* at 200 mg/kg and 400 mg/ kg bwt extracts were able to significantly lower  
173 the blood glucose respectively when compared to the alloxan treated group.

174 Both extracts compared favorably with the reference drug, **Glibenclamide** and the highest effect was  
175 observed in *A. Melegueta* at 200 mg/kg bwt. The observed anti-hyperglycemia activity of these extracts  
176 may be attributed to the presence of phytochemicals such as: total phenols, flavonoids, alkaloids, tannins,  
177 terpenoids, and saponins in the plants that have been known to have anti-hyperglycemic activity [30]. The  
178 presence of these bioactive compounds was earlier reported by our previous studies [10, 31]. Studies also  
179 reported that flavonoids have anti-hyperglycemic properties because they stimulate glucose uptake in  
180 peripheral tissues and attenuate oxidative stress during diabetic conditions [32, 33]. Flavonoids have been  
181 reported to be actively involved in the restoration of pancreatic  $\beta$ -cell and insulin secretion. A large  
182 number of alkaloids have been isolated from numerous medicinal plants and investigated for their possible  
183 anti-hyperglycemic activity [34]. Saponins are known to be efficiently involved in the restoration of  
184 pancreatic  $\beta$ -cell and insulin secretion [32, 35].

185  
186 One of the associated metabolic disorders of diabetes is dyslipidemia which is one of the risk factors of  
187 diabetes [36]. Hypercholesterolemia and hypertriglyceridemia have been reported to occur in alloxan  
188 treated rats [37, 38]. The elevated values for lipid profile: TC, TG, LDL-cholesterol, observed in the  
189 alloxan induced diabetic rats could be partly due to increased intestinal biosynthesis of cholesterol  
190 because diabetes shifted the major site of cholesterologenesis from the liver to the small intestine leading to  
191 hypercholesterolemia [39]. Severe diabetes mellitus due to insulin deficiency might be accompanied with  
192 a reduced LDL-receptor resulting to high concentration of serum LDL cholesterol in diabetic subjects  
193 [40].

194 The results of the extracts treated groups revealed a significant reduction in the levels of total cholesterol,  
195 triglyceride, LDL but an increase in HDL when compared to the alloxan-treated group. The anti-  
196 hyperlipidemic effect was more apparent in the *A. melegueta* treated group at 200 and 400 mg/kg bwt.  
197 This revealed the **anti-hyperlipidemic activity** of the plant extracts. The ability of *A. melegueta* and *P.*  
198 *guineense* to ameliorate the lipid profile may be attributed to the presence of phytochemicals in the plants.  
199 Epidemiological studies have shown that bioactive compounds such as flavonoids intake are inversely  
200 related to mortality from coronary heart diseases and the incidence of heart attacks [41].

201  
202 In conclusion, the results of this study revealed that the plant extracts elicited anti-hyperglycemic effect  
203 and normalized the lipid profile of diabetic rats. This study showed that these spices do not just impact



204 flavour to foods, but may be sources of bioactive substances useful in the treatment and management of  
205 diabetes and related disorders.

### 206 **Ethical Approval:**

207  
208 As per international standard or university standard ethical approval has been collected and preserved by  
209 the authors.

210

### 211 **REFERENCES**

- 212 1. Deguchi Y, Miyazaki K. Anti-hyperglycaemic and anti-hyperlipidemic effects of guava leaf  
213 extract. *Nutrition and Metabolism*. 2010; 7:1-10.
- 214 2. Maruthapan V, Shree K. Antihyperlipidemic potential of a polyherbal drug (Geriforte) on  
215 atherogenic diet induced hyperlipidemia: A Comparison with Ayurslim. *International Journal of*  
216 *Chemical and Analytical Science*. 2010; 3, 37-39.
- 217 3. Sudasinghe HP, Peiris DC. Hypoglycemic and hypolipidemic activity of aqueous leaf extract  
218 of *Passiflora suberosa* L. *PeerJournal*. 2018; 6, e4389; DOI 10.7717/peerj.4389
- 219 4. Dolui AK, Segupta R. Anti-hyperglycemic effect of different extracts of leaves of  
220 *Cajanus cajan* HPLC profile of the active extracts. *Asian Journal of Pharmaceutical and Clinical*  
221 *Research*. 2012; 5:116–119.
- 222 5. Etim OE, Egbuna CF, Odo NM, Awah, FM. In vitro antioxidant and nitric oxide scavenging  
223 activities of *Piper guineense*. *Global Journal of Research in Medical Plants and Indigenous*  
224 *Medicine*. 2013; 2: 485–494.
- 225 6. Martins AP, Salgueiro L, Vila R, Tomi F, Canigual S, Casanova J, Proenca DA, Cunha A,  
226 Adzet T. Essential oils from four *Piper* Species. *Phytochemistry*. 1558, 49, 2019-2023.
- 227 7. Fajobi OA, Fasakin OW, Oyedapo, OO. 2017. Phytochemicals, Antioxidant Potentials, and 2,  
228 2'-diphenyl-1-picryldrazyl (DPPH) Radical Scavenging Activity of *Piper guineense*  
229 (Schumacher & Thonn.) Seed. *African Journal of Plant Science*. 2017; 11: 99-104.
- 230 8. Adewoyin FB, Odaibo AB, Adewunmi CO. Mosquito repellent activity of *Piper guineense* and  
231 *Xylopiiaethiopica* fruit oils. *African Journal of Traditional Complementary Alternative Medicine*.  
232 2006; 3(2): 79-83.

- 233 9. DawareMB, Mujumdar AM, Ghaskadbi S. Reproductive toxicity of piperine in Swiss albino  
234 mice. *Planta Medicine* 2000; 66:231-236.
- 235 10. NwaehujorCO, Eban LK, Ode JO, Ejiofor CE, Igile GO. Hepatotoxicity of methanol seed extract  
236 of *Aframomum melegueta* [Roscoe] K. Schum (Grains of paradise) in Sprague-Dawley  
237 rats. *American Journal of Biomedical Research*. 2014; 2: 61–66.
- 238 11. Alaje DO, Owolabi KT, Olakunle TP, Oluoti OJ, Adetuberu IA. Nutritional, minerals and  
239 phytochemicals composition of *Garcinia kola* [Bitter cola] and *Aframomum melegueta* (Alligator  
240 pepper). *IOSR Journal of Environmental Science, Toxicology And Food Technology*. 2014; 8: 86–  
241 91.
- 242 12. Owokotomo IA, Ekundayo O, Oguntuase BJ. Chemical constituents of the leaf, stem, root and  
243 seed essential oils of *Aframomum melegueta* (K. Schum) from South West Nigeria. *International  
244 Research Journal of Pure and Applied Chemistry*. 2013; 4: 395–401.
- 245 13. El-Halawany AM, El-Dine RS, El-Sayed NS, Hattor IM. Protective effect of  
246 *Aframomum melegueta* phenolics against CCl<sub>4</sub>-induced rat hepatocytes damage; role of apoptosis  
247 and pro-inflammatory cytokines inhibition. *Science Reports*. 2014; 30: 5880.
- 248 14. Ajaiyeoba EO, Ekundayo O. Essential oil constituents of *Aframomum melegueta* (Roscoe) K.  
249 Schum seeds (alligator pepper) from Nigeria. *Flavour and Fragrance Journal*. 2009; 14: 109–111.
- 250 15. Iwu MM. *Handbook of African Medicinal Plants*. Second Edition, CRC Press, Taylor and  
251 Francis Group, Florida, USA.
- 252 16. Ajaiyeoba EO, Ekundayo O. Essential oil constituents of *Aframomum melegueta* (Roscoe) K.  
253 Schum. seeds (alligator pepper) from Nigeria. *Flavour and Fragrance Journal*. 1999; 14: 109–111.
- 254 17. Gabriel AO, Makinde O, Kolawole Falade O, Phyllis I, Peters U. Extraction and  
255 characterization of antioxidants from *Aframomum melegueta* and *Xylopiya aethiopicum*. *European  
256 Food Research and Technology* 2003; 216: 526–528.
- 257 18. Jazet PM, Fekam BF, Sameza ML, Ndongson DB, Kwazou NL, Amvam PH, Menut C.  
258 Investigations on the essential oils of some *Aframomum* species (Zingiberaceae) from Cameroon  
259 as potential antioxidant and anti-inflammatory agents. *International Journal of Essential Oil  
260 Therapeutics*. 2008; 2: 149–155.
- 261 19. Juliani HR, Welch C, Asante-Dartey J, Acquaye D, Wang M, Simon JE. Chemistry, quality,  
262 and functional properties of grains of paradise (*Aframomum melegueta*), a rediscovered. *Dietary  
263 Supplements*. 2008; 6: 100–113.

- 264 20. Umukoro S, Ashorobi RB. Further evaluation of the anti-inflammatory activity of  
265 *Aframomum melegueta* seed extract and its possible mechanism of action. Nigerian Journal Health  
266 Biomedical Sciences 2005; 4: 35–39.
- 267
- 268 21. Mojekwu TO, Yama OE, Ojokuku SA, Oyebadejo SA. Hypoglycemic effects of aqueous  
269 extract of *Aframomum melegueta* leaf on alloxan-induced diabetic male albino rats. Pacific Journal  
270 of Medical Sciences. 2011; 8: 28 – 36.
- 271 22. Bode SO, Oyedapo OO. Biological activities and phytoconstituents of the lower plant  
272 *Platyserium angolense*, Welwex Hook. Journal of Medicinal Plants Research. 2011; 5: 1321-1329.
- 273 23. Ilic N, Schmidt BM, Poulev A, Raskin I. Toxicological evaluation of grains of paradise  
274 (*Aframomum melegueta*) [Roscoe] K. Schum. Journal of Ethnopharmacology. 2010; 127: 10–17.  
275 doi:10.1016/j.jep.2009.10.031
- 276 24. Onoja SO, Ezeja MI, Omeh YN, Emeh EC. Phytochemical and Hypolipidemic Effects of  
277 Methanolic Extract of *Aframomum melegueta* Seed. European Journal of Medicinal Plants. 2015;  
278 5(4): 377-383.
- 279 25. Okoye CN, Obasi OL, Ezechukwu O. Effects of methanolic leaf extract of piper guineense on  
280 some reproductive parameters of male albino rats (*Rattus norvegicus*). Animal Research  
281 International. 2016; 13(3): 2548 – 2553
- 282 26. Ohno T, Horio F, Tanaka S, Terada M, Namikawa TA. Fatty liver and hyperlipidemia in IDDM  
283 (insulin dependent diabetes mellitus) of Streptozotocin treated shrews. Journal of Life Science.  
284 2000; 66(2): 125-131.
- 285 27. Lenzen S. Review: The mechanisms of alloxan- and streptozotocin-  
286 induced diabetes. Diabetologia. 2008; 51: 216–226.
- 287 28. Zafar M, Naeem-Ul H, Aaqvi A, Ahmed A. Altered liver morphology and enzymes  
288 in streptozotocin induced diabetic rats. International Journal of Morphology. 2009; 23: 719-725.
- 289 29. Badin JK, Kole A, Stivers B, Progar V, Paredy A, Alloosh M, Sturek M. Diabetes  
290 Exacerbates Coronary Atherosclerosis in Ossabaw Miniature Swine with Metabolic Syndrome.  
291 Journal of Translational Med. 2018; 16(1): 58.
- 292 30. Middleton EJ, Kandaswami C, Theoharis CT. The effects of plant flavanoids on mammalian  
293 cells: implications for inflammation, heart disease and cancer. Pharmacological Reviews.  
294 2000; 52: 673-751.

- 295 31. Morakinyo AE, Oyedapo OO, Akinpelu BA, Fajobi AO, Fasakin WO, KomolafeIJ, Akinlalu  
296 AO. (2018). Evaluation of Antioxidant, Anti-inflammatory and Phytochemical Constituents of  
297 *Aframomum melegueta* Aqueous Leaf Extract. International Journal of Medicinal  
298 Plants. 2018;112: 888-903.  
299
- 300 32. Echo IA, Osuagwu AN, Agbor RB, Okaka EC, Ekanem BE. Phytochemical composition of  
301 *Aframomum melegueta* and *Piper guineense* seeds. World Journal of Applied Environmental  
302 Chemistry. 2012; 2:17–21.  
303
- 304 33. Eid HM, Martineau LC, Saleem A, Muhammad A, Vallerand D, Benhaddou-Andaloussi, A.  
305 Stimulation of AMP-activated protein kinase and enhancement of basal glucose uptake in muscle  
306 cells by quercetin and quercetin glycosides, active principles of the antidiabetic medicinal plant  
307 *Vaccinium vitis-idaea*. Molecular Nutrition and Food Research. 2010; 54(7): 991-1003.  
308
- 309 34. Rauter AP, Martins A, Borges C, Mota-Filipe H, Pinto R, Sepodes B. Anti-hyperglycaemic  
310 and protective effects of flavonoids on streptozotocin-induced diabetic rats. Phytotherapy  
311 Research. 2010; 24: S133-138.  
312
- 313 35. Aniszewski T. Alkaloids: chemistry, biology, ecology, and applications. 2nd ed. Amsterdam:  
314 Elsevier. 2015; pp 1–475  
315
- 316 36. Preuss HG, Bagchi D, Bagchi M, et al. Effects of a natural extract of (-)-hydroxycitric acid  
317 (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and *Gymnema sylvestre*  
318 extract on weight loss. Diabetes Obesity Metabolism 2004; 6: 171–180.  
319
- 320 37. Chéhade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence,  
321 pathophysiology, and management Drugs. 2013; 73(4): 327-339.  
322
- 323 38. Wang L, Zhang XT, Zhang HY, Yao HY, Zhang H. Effect of *Vaccinium bracteatum* Thunb.  
324 leaves extract on blood glucose and plasma lipid levels in streptozotocin-induced diabetic  
325 mice. Journal of Ethnopharmacology. 2010; 130(3): 465-9.  
326
- 327 39. Balamurugan R, Ignacimuthu, S. Antidiabetic and hypolipidemic effect of methanol extract of  
328 *Lippia nodiflora* L. in streptozotocin induced diabetic rats. Asian Pacific Journal of  
329 Tropical Biomedicine 2011;1: S30-36.  
330
- 331 40. Luka C, Tijjani H, Joel E, Ezejiofor U, Onwukike P. Hypoglycaemic properties of aqueous  
332 extracts of *Anacardium occidentale*, *Moringa oleifera*, *Vernonia amygdalina* and

327 *Helianthus annuus*: A comparative study on some biochemical parameters in diabetic  
328 rats. International Journal of Pharmaceutical Science Invention. 2013; 2: 16-22.

329 41. Swami S, Sztalryd C, Kraemer FB. Effects of streptozotocin-induced diabetes on low density  
330 lipoprotein receptor expression in rat adipose tissue. Journal of Lipid Research. 1996; 37: 229-239.

331

332

UNDER PEER REVIEW